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INTRODUCTION 
Helicobacter pylori (H. pylori) has been estimated to 
affect more than half of the world’s population.1 It is a 
major cause of majority of gastroduodenal diseases.
2
 The 
prevalence of H. pylori associated infections is extremely 
variable and mostly depends on various factors including 
geographical location, socioeconomic factors, and 
personal hygiene.
3
 
Treatment of H. pylori associated infections involves the 
use of antibiotics. However, such treatments are prone to 
failure for a number of reasons. One of the reasons for 
failure is the potential resistance of H. pylori towards one 
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of the antibiotics used in the treatment regimens.4 
Therefore, randomized controlled trials (RCTs) are 
needed to make comparisons between these regimens and 
achieve a maximum eradication rate for H. pylori 
especially in high resistance areas. 
Randomized controlled trials (RCTs) are a type of 
scientific experiments that are often considered as the 
gold standard for measuring the effectiveness of an 
intervention.
5
 However, inappropriate or poor reporting 
of RCTs can produce biased estimates of treatment 
effects.
6-8
 
The consolidated standards of reporting trials 
(CONSORT) statement is a reporting guideline that was 
developed to help the researchers in improving the 
reporting of RCTs. It was first published in 1996 and was 
further updated in 2001 and 2010. It consists of a 25-item 
checklist and was the first reporting guideline to be 
widely published and adopted.
9-11
 
Evidence suggests that the methodological quality of 
reporting of RCTs published in major hepato-
gastroenterology journals improved after the first revision 
of CONSORT in 2001.
12
 However, to the best of authors’ 
knowledge, no review has been done that has assessed the 
quality of reporting of RCTs published in 
gastroenterology journals since the last revision of 
CONSORT in 2010. This review therefore, aims to assess 
the quality of reporting of H. pylori specific randomized 
controlled trials published in highly ranked 
gastroenterology journals by using the CONSORT 2010 
checklist. 
METHODS 
Data sources  
All issues of 20 gastroenterology journals published from 
Jan 2011 up to November 2017 were searched. Since the 
CONSORT statement was last updated in the year 2010, 
the authors limited the search to six years (2011-2017). 
The included journals were top ranked according to 
Thomson Reuter journal citation report 2014 (see Table 1 
for the description of included journals). All these 
journals endorse the CONSORT (Consolidated Standards 
of Reporting Trials) as stated in their author guidelines.
13
 
Searches were conducted in November 2017.  
Study selection 
All RCTs that included H. pylori infection in the title and 
abstract were included in the study and were retrieved as 
a full paper through hand flipping. Authors excluded non-
inferiority RCTs, phase I or phase II studies, community-
based studies, observational studies, meta-analysis, 
diagnostic or screening tests, follow-up studies of 
previously reported RCTs, editorials and letters to editor. 
Data extraction and analysis 
Descriptive data were analysed by SPSS software 
(version 16, IBM SPSS). All included studies were 
evaluated against the CONSORT 2010 checklist to 
evaluate the quality of reporting in RCTs by evaluating 
the internal and external validity of all sections of RCTs, 
including introduction, methods, results and 
conclusions.
10
 The CONSORT 2010 checklist consists of 
25 items. However, authors only used a revised 24 items 
checklist after excluding one item (see appendix 1 for 
CONSORT checklist). Items that were included in the 
checklist were critical to the strength of the RCTs based 
on the current evidence and exclusion of any of these 
items would have been associated with a greater level of 
bias.
14
  
Each item of CONSORT checklist was assessed by 
indicating “Yes” if it was reported in the study and “No” 
if it was either not reported or was unclear. For items that 
were not applicable to the study were reported as “Not 
applicable” e.g. for an open label study, blinding was 
reported as not applicable. An individual score and 
percentage was calculated for all the 24 items in the 
checklist.
15
 The possible score range was between 0 and 
24.  
Data extraction was carried out independently on each 
article by three authors (MM, AM and JS). Any 
differences were resolved through discussion and further 
resolved through the involvement of a fourth reviewer 
(ME). 
RESULTS 
Initial searches in the included gastroenterology journals 
identified 89 studies. Of these 89, 68 were excluded due 
to ineligibility (52 Not RCTs, 2 Inferior studies, 1 
Abstract, and 13 Editorials). Finally, 21 studies were 
included in the review.
16-36
 
Study characteristics 
Of the 21 included studies, eight were published in 
journal of gastroenterology, six in alimentary 
pharmacology and therapeutics, three in GUT, three in 
the American journal of gastroenterology, followed by 
one in the Clinical Gastroenterology and Hepatology (see 
Table 1 for description of included RCTs). 12 of the 
included RCTs were conducted in multicentre and seven 
used a single centre. The two remaining studies did not 
report their setting. Seven of the included studies were 
conducted in Japan, four each in China and South Korea, 
two in Hong Kong followed by one each in USA, Israel, 
Spain and United Kingdom (see Table 2 for 
characteristics of included RCTs).  
Reporting of CONSORT items in the included studies  
All included studies adequately reported (100%) on items 
including description of interventions, outcomes 
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assessed, total number of participants analysed, baseline 
characteristics and results of outcome assessed. However, 
items including blinding and mechanism of allocation 
concealment was reported in only 12 randomized 
controlled trials (50%). Details of trial design were 
provided in 11 (45.8%) studies. 14 (58.3%) studies 
reported how sample size was calculated. Statistical 
methods used for comparison of outcomes between the 
treatment groups were reported in 23 (95.8%) studies 
while 10 (41.6%) studies provided the details of 
additional analysis including subgroup analysis in their 
study (see Table 3 for the assessment of compliance of 
included RCTs with the CONSORT checklist). 
Table 1: Description of journals included in the review. 
Journal name 
Impact 
factor* 
Number of articles 
identified (n=89) 
Number of 
included articles 
(n=21) 
Gastroenterology  16.716 29 0 
GUT 14.660 22 3 
Nature reviews gastroenterology and hepatology 13.678 0 0 
Hepatology 13.246 0 0 
Journal of hepatology 12.486 0 0 
American journal of gastroenterology  10.755 13 3 
Clinical gastroenterology and hepatology  7.398 10 1 
Liver Cancer 7.854 0 0 
Alimentary pharmacology & therapeutics 7.286 6 6 
Gastrointestinal endoscopy 6.501 0 0 
Endoscopy 6.107 0 0 
Journal of crohns & colitis 5.813 0 0 
Seminars in liver disease journal 5.5 0 0 
Gastric cancer 5.454 0 0 
Inflammatory bowel diseases 4.525 0 0 
Journal of gastroenterology 4.493 9 8 
Journal of viral hepatitis 4.122 0 0 
Liver international 4.116 0 0 
Clinical and translational gastroenterology 3.923 0 0 
Liver transplantation 3.910 0 0 
*The impact factor according to web of Science-ISI Thomson Reuters 2014. 
Table 2: Characteristics of included RCTs. 
Characteristic n= 21 (%) 
Number of authors  
6 1 (4.7) 
7 1 (4.7) 
8 3 (14.3) 
9 2 (9.5) 
10 1 (4.7) 
11 2 (9.5) 
13 2 (9.5) 
14 5 (23.8) 
15 1 (4.7) 
5 1 (4.7)  
23 1 (4.7) 
29 1 (4.7) 
Center  
Single 7 (33.33) 
Multicenter 12 (57.14) 
Not reported 2 (9.5) 
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Characteristic n= 21 (%) 
Year of publication  
2011 6 (28.5) 
2012 5 (23.8) 
2013 5 (23.8) 
2014 5 (23.8) 
Type of intervention  
Active control 15 (71.4) 
Placebo control  6 (18.6) 
Type of funding   
Government 5 (23.8) 
Academic & research centers 4 (19) 
Not reported 6  (28.5) 
Pharmaceutical companies & others 6 (28.5) 
Study design   
Crossover 1 (4.7) 
Parallel 19 (90.5) 
Factorial 2x2  1 (4.7) 
Randomization   
Block 11 (52.3) 
Stratified block  1 (4.7) 
Computer generated or 3rd party 6 (28.5) 
Unknown 3 (14.3) 
Blinding   
Open label 12 ( (57.14) 
Single-blind 1 (4.7) 
Double-blind  7 (33.33) 
Double-dummy 1 (4.7) 
Impact factor   
4.493 8 (38.1) 
7.286 6 (28.5) 
7.896  1 (4.7) 
10.755  3 (14.3) 
14.660 3 (14.3) 
Country of study  
Hong Kong 2 (9.5) 
Spain  1 (4.7) 
China 4 (19) 
South Korea  4 (19) 
USA  1 (4.7) 
UK 1 (4.7) 
Israel 1  (4.7) 
Japan 7 (33.33) 
Table 3: Assessment of compliance of included studies with the CONSORT checklist. 
Section Item No Assessment of included RCTs (n=21) (%) 
Title and abstract  
 1 18 (75) 
 2 21 (87.5) 
Methods  
Trial design 3 11 (45.8) 
Participants 
4 18 (75) 
5 13 (54.1) 
Interventions 6 24 (100) 
Outcomes 7 24 (100) 
Sample size 8 14 (58.3) 
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Section Item No Assessment of included RCTs (n=21) (%) 
Randomization 
Sequence generation 
9 12 (50) 
10 11 (45.8) 
Allocation concealment mechanism 11 12 (50) 
Blinding 12 12 (50) 
Statistical methods 
13 23 (95.8) 
14 10 (41.6) 
Results 
Participant flow (a diagram is strongly 
recommended) 
15 19 (79.1) 
16 17 (70.8) 
Recruitment 17 19 (79.1) 
Baseline data 18 24 (100) 
Numbers analyzed 19 24 (100) 
Outcomes and estimation 20 24 (100) 
Discussion 
Limitations 21 18 (75) 
Other information 
Registration 22 11 (45.8) 
Protocol 23 4 (16.6) 
Funding 24 18 (75) 
Table 4: Scores and percentage of compliance of included studies with CONSORT checklist. 
No. Included RCTs Journal Score 
Percentage of 
compliance (%) 
1 Liu et al.  GUT 24 100 
2 McNicholl et al.  GUT 24 100 
3 Wong et al.  GUT 18 75 
4 Park et al.  American Journal of Gastroenterology 18 75 
5 Zhou et al. American Journal of Gastroenterology 20 83.33 
6 Basu et al. American Journal of Gastroenterology 15 62.50 
7 Liang et al.  Clinical Gastroenterology and Hepatology 19 79.17 
8 Cho et al. Alimentary Pharmacology and Therapeutics 18 75 
9 Huang et al. Alimentary Pharmacology and Therapeutics 17 70.83 
10 Lane et al.  Alimentary Pharmacology and Therapeutics 22 91.66 
11 Kim et al.  Alimentary Pharmacology and Therapeutics 21 87.5 
12 Park et al.  Alimentary Pharmacology and Therapeutics 18 75 
13 Nseir et al.  Alimentary Pharmacology and Therapeutics 18 75 
14 Murakami et al. Journal of Gastroenterology 14 58.33 
15 Sugano et al.  Journal of Gastroenterology 19 79.17 
16 Sanuki et al.  Journal of Gastroenterology 17 70.83 
17 Sugano et al.  Journal of Gastroenterology 16 66.66 
18 Fujiwara et al.  Journal of Gastroenterology 18 75 
19 Tominaga et al.  Journal of Gastroenterology 21 87.5 
20 Tan et al.  Journal of Gastroenterology 17 70.83 
21 Nagahara et al.  Journal of Gastroenterology 16 66.66 
 
 
The maximum scores and percentage of compliance of 
included RCTs were 24 and 100% respectively while the 
minimum scores and percentage of compliance were 15 
and 62.50% respectively (see table 4 for scores and 
percentage of compliance of included RCTs with 
CONSORT checklist). 
DISCUSSION 
This is the first review that has assessed the quality of 
reporting of H. pylori related randomized controlled trials 
by using a 2010 CONSORT checklist. In general the 
overall quality of reporting of included RCTs was 
adequate. All included studies adequately reported on 
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items including description of interventions, outcomes 
assessed and baseline characteristics. However, items 
including trial design, trial registration and protocol were 
not reported adequately in the included studies. 
This review reported a similar percentage of studies that 
reported the mechanism of allocation concealment (50%) 
as reported in previous studies.
37,38
 Similarly, compliance 
of the studies included in this review with CONSORT 
items such as the reporting of flow diagram was higher 
(79.1%) as compared to earlier studies.
39,40
 These 
findings suggest an increase in the compliance of RCTs 
with the CONSORT items in particular, reporting of flow 
diagram. However, fewer studies (45.8%) included in this 
review reported their trial design as compared to 100% of 
the studies included in another study.
15
  
Only 12 (50%) of the included studies reported how 
sample size was calculated. Sample size calculations are 
critical to clinical research and ensure that sufficient 
number of participants required for determining the 
safety and efficacy of the study intervention have been 
enrolled in the study. Failure to report sample size 
calculations by authors raises the concern of the validity 
of their study findings and should therefore be reported 
adequately in the study.  
Clinical trials that do not use the CONSORT statement 
for reporting their findings will have limited value to the 
clinicians and researchers due to the risk of bias in 
results. Authors of this review would therefore, 
recommend all gastroenterology journals to endorse the 
CONSORT statement on their websites to improve the 
reporting of RCTs. Authors should be required to submit 
the CONSORT checklist when submitting new 
manuscripts to ensure more accurate and robust reporting 
of RCTs. Indeed, reviewers and Editorial office should 
ensure that the CONSORT checklist is fulfilled.  
This review has some limitations. Although rigorous and 
systematic, the reviewers did not include unindexed and 
unpublished research. Furthermore, the number of studies 
that were included in this review was low. The findings 
of this review are therefore only applicable to the 
included journals and cannot be extrapolated to other 
journals that may affect the generalizability of the 
findings of this review. 
CONCLUSION 
The findings of this review suggest that the overall 
quality of reporting of included RCTs was adequate. 
However, items including trial design, trial registration 
and protocol and sample size calculations should be 
reported adequately in the future RCTs to improve the 
quality of reporting. 
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APPENDIX 1 
24 item CONSORT checklist. 
Section Item no Checklist item 
Title and abstract  
 1 Identification as a randomised trial in the title  
 2 
Structured summary of trial design, methods, results, and conclusions (for 
specific guidance see CONSORT for abstracts)  
Methods  
Trial design 3 
Description of trial design (such as parallel, factorial) including allocation 
ratio 
Participants 
4 Eligibility criteria for participants 
5 Settings and locations where the data were collected 
Interventions 6 
The interventions for each group with sufficient details to allow replication, 
including how and when they were actually administered 
Outcomes 7 
Completely defined pre-specified primary and secondary outcome measures, 
including how and when they were assessed 
Sample size 8 How sample size was determined 
Randomisation   
Sequence generation 
9 Method used to generate the random allocation sequence 
10 
Type of randomisation; details of any restriction (such as blocking and block 
size) 
Allocation concealment 
mechanism 
11 
Mechanism used to implement the random allocation sequence (such as 
sequentially numbered containers), describing any steps taken to conceal the 
sequence until interventions were assigned 
Blinding 12 
If done, who was blinded after assignment to interventions (for example, 
participants, care providers, those assessing outcomes) and how 
Statistical methods 
13 
Statistical methods used to compare groups for primary and secondary 
outcomes 
14 
Methods for additional analyses, such as subgroup analyses and adjusted 
analyses 
Results 
Participant flow (a diagram 
is strongly recommended) 
15 
For each group, the numbers of participants who were randomly assigned, 
received intended treatment, and were analysed for the primary outcome 
16 
For each group, losses and exclusions after randomisation, together with 
reasons 
Recruitment 17 Dates defining the periods of recruitment and follow-up 
Baseline data 18 
A table showing baseline demographic and clinical characteristics for each 
group 
Numbers analysed 19 
For each group, number of participants (denominator) included in each 
analysis and whether the analysis was by original assigned groups 
Outcomes and estimation 20 
For each primary and secondary outcome, results for each group, and the 
estimated effect size and its precision (such as 95% confidence interval) 
Discussion 
Limitations 21 
Trial limitations, addressing sources of potential bias, imprecision, and, if 
relevant, multiplicity of analyses 
Other information 
Registration 22 Registration number and name of trial registry 
Protocol 23 Where the full trial protocol can be accessed, if available 
Funding 24 
Sources of funding and other support (such as supply of drugs), role of 
funders 
*The descriptors describing each CONSORT item used are taken directly from the “CONSORT 2010 Statement: updated guidelines for 
reporting. 
